title: Botulinum toxin type A for the treatment of chronic neck pain after neck dissection.
abstract: BACKGROUND
  Neck dissection surgery is often followed by chronic head and neck pain. To date optimal treatment of this type of pain is lacking. Botulinum toxin type A (BTX-A) has been shown to be effective in the treatment of myofascial pain syndrome and headache. In a pilot study, we wanted to test the effectiveness of BTX-A for the treatment of chronic neck pain after neck dissection.
  
  
  METHODS
  Sixteen patients with chronic neck pain after neck dissection were included in this prospective, open study. Eighty to 320 units of BTX-A (Dysport) were injected into muscular trigger points. Outcome measures included chronic pain and shooting pain on the basis of visual analog scales and quality of life improvement (EORTC QLQ-C-30; EORTC QLQ-H and N35) before and 4 weeks after treatment.
  
  
  RESULTS
  Patients showed a significant reduction in chronic pain (4.5 before to 3.3 after treatment, p =,005) and in shooting pain (6.1 before to 4.7 after treatment, p =.005). There was a trend toward improvement in global quality of life (QLQ-C30, p =.097) and an increase on the functional scale "pain" (QLQ-H and N35, p =.071).
  
  
  CONCLUSIONS
  BTX-A treatment of subjects with chronic neck pain after neck dissection resulted in a fast and significant reduction of pain. A significant improvement in quality of life may be expected in a longer time course after treatment.
authors.affiliation: University Hospital Cologne, Department of Otorhinolaryngology, Head and Neck Surgery, Joseph-Stelzmann-Strasse 9, D-50924 Koeln, Germany. claus.wittekind@uni-koeln.de
authors.forename: Claus Wittekindt
authors.initials: CW
authors.lastname: Vasan
authors.forename: Wei-Chi
authors.initials: WC
authors.lastname: Liu
authors.forename: Jens-Peter
authors.initials: JP
authors.lastname: Klussmann
authors.forename: Orlando
authors.initials: O
authors.lastname: Guntinas-Lichius
mesh_terms: D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D037981:Neck Dissection / Q000009:adverse effects*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement; D010865:Pilot Projects; D011446:Prospective Studies; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A